| h-fca0433042 | Microglial IFN-β Priming of Motor Neuron cGAS/STING Amplification | 0.72 | 0.70 | IFNAR1/IFNAR2, STING (TMEM173), cGAS (CGAS) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046 |
| h-7881847161 | Pharmacologic activation of GBA1 to reduce alpha-synuclein burden in Parkinson's | 0.72 | 0.85 | GBA1 | proposed | 2026-05-01 | SDA-2026-05-01-gap-test-20260425-224949 |
| h-a5bc82c685 | Excessive C1q/C3/CR3 complement cascade activation initiates pre-symptomatic syn | 0.72 | 0.72 | C1QA, C1QB, C1QC, C3, ITGAM/ITGAX | proposed | 2026-04-22 | SDA-2026-04-02-gap-synaptic-pruning-microglia |
| h-6756097b | ASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis | 0.72 | 0.68 | FUS | promoted | 2026-04-14 | SDA-2026-04-14-gap-pubmed-20260410-184155-2ff305ca |
| h-056cb87f4e | NLRP3 Inflammasome Inhibition for Neuroprotection in Parkinson's Disease | 0.72 | 0.72 | NLRP3 | proposed | 2026-04-28 | SDA-2026-04-28-gap-test-20260425-224949 |
| h-90b7b77f59 | Bacterial Curli Amyloid → Nucleation of α-Synuclein Misfolding in Enteric Neuron | 0.72 | 0.72 | CsgA, CsgB, CsgC, α-synuclein (SNCA) | proposed | 2026-04-22 | sda-2026-04-01-gap-20260401-225155 |
| h-7af6de6f2a | NLRP3 Inflammasome Lock Perpetuates Senescence-Associated Inflammasome Phenotype | 0.72 | 0.72 | NLRP3/CASP1/IL1B | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041439-5f43216e |
| h-9ff41c2036 | H6: Layer II–Specific Loss of NPTX2 and Aberrant AMPAR Trafficking | 0.72 | 0.75 | NPTX2, ARC | proposed | 2026-04-22 | SDA-2026-04-02-gap-ec-layer2-vulnerability |
| h-c410043ac4 | Antisense Oligonucleotide-Mediated APOE4 Haploinsufficiency | 0.72 | 0.75 | APOE | proposed | 2026-04-22 | SDA-2026-04-02-gap-apoe4-targeting |
| h-97aa8486 | Stress Granule Phase Separation Modulators | 0.72 | 0.80 | G3BP1 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-aa2d317c | Magnetosonic-Triggered Transferrin Receptor Clustering | 0.72 | 0.65 | TFR1 | debated | 2026-04-02 | sda-2026-04-01-gap-008 |
| h-35f04e1b | Retinal Vascular Microcirculation Rescue | 0.72 | 0.40 | PDGFRB/ANGPT1 | debated | 2026-04-02 | sda-2026-04-01-gap-012 |
| h-3a990993 | Compromised Lysosomal Acidification and Trafficking Due to Neuronal V-ATPase Sub | 0.72 | 0.75 | ATP6V0/ATP6V1 subunits, ARL8B-SYX17 axis | proposed | 2026-04-26 | SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c |
| h-trem2-f3effd21 | TREM2-DAP12 Signalosome Enhancement — Boosting PI3K-AKT-mTOR Axis for Microglial | 0.72 | 0.62 | TREM2, TYROBP, SYK, PI3K | proposed | 2026-04-04 | SDA-2026-04-02-gap-001 |
| h-15336069 | APOE Isoform Conversion Therapy | 0.72 | 0.45 | APOE | proposed | 2026-04-02 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| h-b948c32c | Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides | 0.72 | 0.30 | APOE, LRP1, LDLR | debated | 2026-04-02 | sda-2026-04-01-gap-008 |
| h-530326b97069 | SASP-Secreted MMP-9 from Senescent Microglia Generates Pathological TDP-43 C-Ter | 0.72 | 0.30 | MMP9 → TARDBP (C-terminal fragments) → cytoplasmic aggregati | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260425215446 |
| h-1111ac0598 | C9orf72 DPRs Impair Autophagy Receptor Docking on Stress Granules | 0.72 | 0.72 | C9orf72, p62/SQSTM1, OPTN | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041423-3a6aa4ab |
| h-var-de1677a080 | TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration | 0.72 | 0.80 | TREM2 | proposed | 2026-04-12 | SDA-2026-04-26-trem2-showcase |
| h-7e0b5ade | Circadian-Synchronized LRP1 Pathway Activation | 0.71 | 0.40 | LRP1, MTNR1A, MTNR1B | debated | 2026-04-02 | sda-2026-04-01-gap-008 |
| h-trem2-fe8c644a | Soluble TREM2 (sTREM2) as Therapeutic Mimic — Decoupling Phagocytosis from Infla | 0.71 | 0.65 | TREM2, ADAM10, ADAM17 | proposed | 2026-04-04 | SDA-2026-04-02-gap-001 |
| h-f373e16bb108 | EZH2-Mediated H3K27me3 Spreading in Senescent ALS Microglia Silences Neuroprotec | 0.71 | 0.28 | EZH2 (PRC2) → H3K27me3 silencing of BDNF, GRN, TREM2, MerTK | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260425215446 |
| h-0758b337 | Purinergic Signaling Polarization Control | 0.71 | 0.70 | P2RY1 and P2RX7 | debated | 2026-04-02 | sda-2026-04-01-gap-007 |
| h-var-18aae53fe9 | TREM2-ASM Crosstalk in Microglial Lysosomal Senescence | 0.71 | 0.78 | SMPD1 | promoted | 2026-04-12 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-1f9e65f394 | Liquid-to-Solid Transition Pathology Reveals Granule Weak Points | 0.71 | 0.82 | TDP-43, FUS, TIA1, G3BP1 | debated | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041428-53b81741 |
| hyp_test_656bc496 | Test: TREM2 enhances amyloid clearance | 0.71 | 0.33 | TREM2 | proposed | 2026-04-17 | test-hypothesis-fixtures-v1 |
| h-583535bb | Gut-BBB Axis: Tributyrin/Butyrate HDAC Inhibition Epigenetically Restores Claudi | 0.71 | 0.74 | CLDN5 | proposed | 2026-04-26 | SDA-2026-04-26-gap-bbb-permeability-biomarker-20260426 |
| h-fcd38787 | TGF-β1–SMAD2/3 Axis as Master Suppressor of Microglial Trained Immunity | 0.71 | 0.78 | TGFBR1/TGFBR2 → SMAD4 → SMAD2/3 | proposed | 2026-04-26 | SDA-2026-04-08-gap-debate-20260406-062033-ad87c3fb |
| h-de579caf | Circadian Glymphatic Rescue Therapy (Melatonin-focused) | 0.71 | 0.55 | MTNR1A | debated | 2026-04-02 | sda-2026-04-01-gap-v2-18cf98ca |
| h-9588dd18 | Early Proteasome Restoration Therapy | 0.71 | 0.75 | PSMC | promoted | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-4113b0e8 | Noradrenergic-Tau Propagation Blockade | 0.71 | 0.45 | ADRA2A | debated | 2026-04-02 | sda-2026-04-01-gap-v2-18cf98ca |
| h-f7d4cdb947 | Gamma entrainment suppresses hippocampal ERK1/2 hyperactivity to decrease AD-rel | 0.71 | 0.72 | MAPK3/MAPK1 (ERK1/2); MAP2K1/MAP2K2 (MEK1/2); RASGRF1 | proposed | 2026-04-28 | SRB-2026-04-28-h-bdbd2120 |
| h-5edc4a7e0558 | Excess orexin-A worsens AD cognition through wake-driven amyloid production | 0.71 | 0.69 | HCRT | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-184240-f72e77ae |
| h-64d92165 | APOE4-Specific Microglial Metabolic Rescue | 0.71 | 0.66 | APOE, ABCA1, LDLR | proposed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| h-a9571dbb | HDAC3-Selective Inhibition for Clock Reset | 0.71 | 0.60 | HDAC3 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-bc5f270e |
| h-d2d37a81eeaa | ACSL4 lipid remodeling creates ferroptosis-prone ALS membranes | 0.71 | 0.69 | ACSL4 | proposed | 2026-04-26 | SDA-2026-04-26-gap-ferroptosis-mnd-768eaeba1be3 |
| h-82634b359b | H4: Senomorphic Compounds Preserve Astrocyte Function While Reversing Senescence | 0.71 | 0.65 | MTOR; MEGF10; MERTK | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0 |
| h-4032affe2f | Microglial Disease-Associated States: TREM2-Independent Pathways Driving Neuroin | 0.71 | 0.68 | APOE | proposed | 2026-04-22 | SDA-2026-04-02-gap-seaad-debate-v4 |
| h-75fd56f128 | RAB29 Is the Critical Molecular Switch That Determines Whether LRRK2 Signal Ampl | 0.71 | 0.70 | RAB29 | proposed | 2026-04-26 | SDA-2026-04-23-gap-debate-20260417-033119-54941818 |
| h-d9793012de | Conformational-Selective Blocking of Tau Uptake Reveals Therapeutic Window in Ne | 0.71 | 0.72 | LRP1, HSPG (SDC3, GPC1), tau conformations | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-7bcf4b6c |
| h-b9794c8e29 | Microglial TREM2 Activation Reduces Amyloid-Associated Neurotoxicity | 0.71 | 0.78 | TREM2 | proposed | 2026-04-28 | SDA-TEST-PREREG-003 |
| h-c8d21880fc | LRRK2 kinase inhibition to normalize lysosomal trafficking in Parkinson's diseas | 0.71 | 0.80 | LRRK2 | proposed | 2026-05-01 | SDA-2026-05-01-gap-test-20260425-224949 |
| h-78c49508e9 | NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD | 0.71 | 0.72 | NFE2L2 (NRF2) | proposed | 2026-04-28 | SDA-TEST-PREREG-003 |
| h-3d993b5d | Metabolic Circuit Breaker via Lipid Droplet Modulation | 0.71 | 0.60 | PLIN2 | debated | 2026-04-02 | sda-2026-04-01-gap-009 |
| h-5e68b4ad | Autophagosome Maturation Checkpoint Control | 0.71 | 0.73 | STX17 | debated | 2026-04-02 | sda-2026-04-01-gap-011 |
| h-82922df8 | Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition | 0.71 | 0.65 | LOX/LOXL1-4 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-immunity-c64967ab | TREM2-APOE4 Axis Drives Metabolic Inflexibility in DAM | 0.71 | 0.72 | TREM2, APOE4, LDHA | open | 2026-04-24 | |
| h-var-bed9f3b7ed | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | 0.71 | 0.80 | TREM2 | superseded | 2026-04-12 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-9d29bfe5 | Membrane Cholesterol Gradient Modulators | 0.71 | 0.85 | ABCA1/LDLR/SREBF2 | promoted | 2026-04-02 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| h-8597755b | Orexin-Microglia Modulation Therapy | 0.71 | 0.50 | HCRTR2 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-18cf98ca |